HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women.
Doggen
C J M
CJ
Department of Epidemiology, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA. C.J.M.Doggen@lumc.nl
Lemaitre
R N
RN
Smith
N L
NL
Heckbert
S R
SR
Psaty
B M
BM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001779:Blood Coagulation Factors / Q000187:drug effects; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D017698:Postmenopause; D017035:Pravastatin / Q000494:pharmacology / Q000627:therapeutic use; D012306:Risk; D019821:Simvastatin / Q000494:pharmacology / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000188:drug therapy*
D001779:Blood Coagulation Factors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol; D019821:Simvastatin; D017035:Pravastatin